TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00579046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections
Study: NCT04794647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical mobilization
Description: A kind of manual therapy tecnique applied to the cervical region

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mobilization
Description: It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
Study: NCT03206632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT00858897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cysteine isotope infusion at normoglycemia vs hyperglycemia
Description: L-\[3,3-2H2\]cysteine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cysteine isotope infusion at normoglycemia vs hyperglycemia
Description: L-\[3,3-2H2\]cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
Study: NCT03158272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03089944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Tablet
Study: NCT01688921

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFLURIA vaccine (2012-2013 formulation)
Description: Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFLURIA vaccine (2012-2013 formulation)
Description: Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle-Syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle-Syringe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stratis needle-free injection device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratis needle-free injection device
Study: NCT06139562

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-Restricted Feeding
Description: Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Time Feeding
Description: Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended-Time Feeding
Description: Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
Study: NCT01389349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Battlefield acupuncture protocol

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham control acupuncture
Study: NCT04073563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infuse™ Bone Graft (Infuse™)
Description: (Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infuse™ Bone Graft (Infuse™)
Description: (Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervertebral body fusion device and Medtronic posterior Fixation Systems
Description: Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervertebral body fusion device and Medtronic posterior Fixation Systems
Description: Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervertebral body fusion device and Medtronic posterior Fixation Systems
Description: Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
Study: NCT03535922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMs Assessment
Description: Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMs Assessment
Description: Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMs Assessment
Description: Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both
Study: NCT06387979

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT04343703

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based management
Description: The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iFightDepression for Suicide
Description: The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Awareness of Mental Health
Description: The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
Study: NCT03362060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
Study: NCT00999193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: locking plate, ORIF
Description: Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Description: Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
Study: NCT04356729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
Study: NCT02742584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough Stress Test
Description: Varying bladder volumes during cough stress test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough Stress Test
Description: Varying bladder volumes during cough stress test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough Stress Test
Description: Varying bladder volumes during cough stress test.
Study: NCT01349790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam
Description: NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
Study: NCT02691143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraBand Kinesiology Tape
Description: One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
Study: NCT03249831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Orally daily
Study: NCT02289690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules administered orally twice a day according to the dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules administered orally twice a day according to the dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules administered orally twice a day according to the dosing schedule.
Study: NCT03054896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: Intensive chemotherapy regiment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: Intensive chemotherapy regiment
Study: NCT03985982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
Study: NCT01065194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
Study: NCT00286195

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Multi-Link Frontier Coronary Stent System
Description: Bare metal stent
Study: NCT04080986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Sequential Defibrillation
Description: Defibrillation using pad placement in anterior-posterior position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vector Change Defibrillation
Description: Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
Study: NCT04221542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 509
Description: AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 509
Description: AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 509
Description: AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 509
Description: AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 509
Description: AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide administered as oral tablets.
Study: NCT02944864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3395
Description: TQ-B3395 p.o. qd
Study: NCT04203069

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group : Day-time compression sleeve
Description: In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit
Description: In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).
Study: NCT02584933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib
Description: hard gelatin capsule or hard tablet for oral use up to 750 mg
Study: NCT01842035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
Study: NCT01713504

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biologie sample
Description: comparison of biomarkers between HES, HE biomarkers data and control arms

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biologie sample
Description: comparison of biomarkers between HES, HE biomarkers data and control arms

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: biologie sample
Description: comparison of biomarkers between HES, HE biomarkers data and control arms
Study: NCT01746511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycerin suppository
Description: Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
Study: NCT02409004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Capsule 2x3oo mg Oral
Study: NCT04644978

Intervention type: OTHER
Intervention: anonymous online survey
Description: An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
Study: NCT01478802

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung protective CMV
Description: Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFO-RMs
Description: Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
Study: NCT01888731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg